Page last updated: 2024-12-10

ee 581

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

EE 581: photosensitive azido derivative of tyrosine(3)-octreotide used to label the somatostatin receptor; amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3036100
MeSH IDM0200722

Synonyms (8)

Synonym
azidophenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-threonyl-cysteinyl-threonin-ol
ee-581
141949-00-0
l-cysteinamide, 4-azido-d-phenylalanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-threonyl-n-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2-7)-disulfide, (r-(r*,r*))-
phe(n3)-cys-tyr-trp-lys-thr-cys-thr-ol
ee 581
(2s)-2-[[(2r)-3-[(1ar)-1a,2-dihydrothiireno[2,3-b]indol-6b-yl]-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-(4-azidophenyl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-n-[(2s,3r)-1-[[(2r)-2-(1,3-dihydroxybutan-2-ylamino)-3-
(2s)-2-((2r)-2-((s)-2-((s)-2-((r)-2-amino-3-(4-azidophenyl)propanamido)propanamido)-3-(4-hydroxyphenyl)propanamido)-3-((1ar)-1a,2-dihydro-6bh-thiireno[2,3-b]indol-6b-yl)propanamido)-n-((2s,3r)-1-((2r)-2-((1,3-dihydroxybutan-2-yl)amino)-3-mercaptopropanami

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX(1)R and OX(2)R currently under clinical investigation as a novel therapy for insomnia."( Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
Breslin, MJ; Coleman, PJ; Cox, CD; Cui, D; Doran, SM; Fox, SV; Garson, SL; Gotter, AL; Harrell, CM; Reiss, DR; Renger, JJ; Stevens, J; Tannenbaum, PL; Winrow, CJ, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" Dosed orally Suvorexant significantly and dose-dependently reduced locomotor activity and promoted sleep in rats (10, 30, and 100 mg/kg), dogs (1 and 3 mg/kg), and rhesus monkeys (10 mg/kg)."( Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
Breslin, MJ; Coleman, PJ; Cox, CD; Cui, D; Doran, SM; Fox, SV; Garson, SL; Gotter, AL; Harrell, CM; Reiss, DR; Renger, JJ; Stevens, J; Tannenbaum, PL; Winrow, CJ, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (7.69)18.2507
2000's4 (30.77)29.6817
2010's8 (61.54)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies1 (7.69%)4.05%
Observational0 (0.00%)0.25%
Other11 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]